Compare ASPI & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPI | ARVN |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 637.1M | 658.2M |
| IPO Year | 2022 | 2018 |
| Metric | ASPI | ARVN |
|---|---|---|
| Price | $4.92 | $9.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 19 |
| Target Price | $12.00 | ★ $15.05 |
| AVG Volume (30 Days) | ★ 4.0M | 721.1K |
| Earning Date | 04-10-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ N/A |
| Revenue | $23,849,000.00 | ★ $262,600,000.00 |
| Revenue This Year | $68.41 | N/A |
| Revenue Next Year | $126.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 475.48 | N/A |
| 52 Week Low | $3.92 | $5.90 |
| 52 Week High | $14.49 | $14.22 |
| Indicator | ASPI | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 31.70 |
| Support Level | $3.98 | $9.02 |
| Resistance Level | $5.90 | $10.18 |
| Average True Range (ATR) | 0.51 | 0.41 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 43.38 | 2.60 |
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.